DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%... Show more
DaVita is one of the two dominant providers of dialysis services in the United States, holding an estimated 35% share of the U.S. market alongside rival Fresenius Medical Care. Its scale across roughly 2,600 U.S. centers serving nearly 200,000 patients creates meaningful bargaining power with suppliers and payers, while its international footprint — about 585 centers serving close to 94,500 patients — provides a second growth engine. Management has described international expansion as roughly half mergers and acquisitions (M&A) and half organic, following recent integrations in Latin America.
Structurally, the company is shifting from a fee-for-service dialysis operator toward an integrated, value-based kidney care platform. The IKC business, which manages patient populations under risk-based contracts, reached profitability a year ahead of its original target. This evolution matters because it moves DaVita toward revenue streams tied to total cost of care and shared savings, rather than purely to treatment volume — a strategic hedge against stagnating dialysis volumes.
The most immediate catalyst is the third-quarter earnings report on October 29, 2026. Investors will focus on treatment volume trends, revenue per treatment (RPT), and whether patient care cost inflation continues to moderate. Management has guided to adjusted operating income of $2.085 billion to $2.235 billion and adjusted EPS growth of roughly 33% at the midpoint, driven by operating leverage, share repurchases, and the removal of prior Mozarc-related headwinds.
The pending close of the Elara Caring investment later in 2026 represents another catalyst. By combining dialysis with skilled home health, personal care, and hospice, DaVita aims to reduce hospitalizations and missed treatments — directly supporting its goal of returning to 2% or better treatment volume growth over time.
Analyst activity has turned more constructive. Deutsche Bank upgraded DaVita to Buy, TD Cowen moved to Buy, and UBS and Deutsche Bank have raised price targets as high as $265 to $270. Consensus is a "Buy" rating with an average one-year price target near $220, though Bank of America's Sell rating highlights a genuine divergence of opinion. The 2027 Medicare Advantage ESKD funding increase of 6% provides a concrete reimbursement catalyst that could reinforce pricing power heading into next year.
DaVita's outlook is closely tied to interest rates and its balance sheet. With leverage of about 3.26 times consolidated EBITDA (earnings before interest, taxes, depreciation, and amortization), the cost of capital directly influences how aggressively management can fund buybacks and M&A. Lower rates would support both earnings growth and valuation.
Inflation remains a persistent factor in a labor-intensive business. Patient care costs per treatment rose 5.9% in 2025, driven by wages, health benefits, and supplies; the pace is expected to moderate but remains a margin risk. On the demand side, an aging population and rising prevalence of chronic kidney disease and diabetes provide a durable secular tailwind, even as elevated post-pandemic mortality temporarily suppresses treatment growth.
Regulatory and reimbursement policy is perhaps the single largest macro variable. The expiration of enhanced premium tax credits creates near-term revenue pressure, while annual Medicare rate-setting directly shapes pricing. Technology adoption — including GLP-1 (glucagon-like peptide-1) therapies, medium-cutoff dialyzers, and hemodiafiltration — could improve patient outcomes and, over time, support volume recovery.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. The tool aims to help users spot developing trends, evaluate potential breakouts or reversals, and explore predictions across a wide range of tradable instruments. It also offers searchable prediction categories, historical context, and alert-oriented functionality to support ongoing monitoring. For investors tracking DaVita's evolving catalyst calendar, the Trend Prediction Engine can provide an additional data-driven lens on short- to medium-term directional signals.
For 2026, DaVita's guidance points to a year defined more by earnings quality and capital allocation than by top-line expansion. Adjusted EPS of $13.60 to $15.00 reflects an expected 33% growth at the midpoint, supported by nearly $1.8 billion in 2025 buybacks, lower interest expense, and incremental IKC profitability. Free cash flow guidance of $1 billion to $1.25 billion gives management flexibility to continue repurchasing shares while pursuing disciplined growth investments.
Longer term, several structural themes will shape the trajectory. Value-based care and integrated care models offer a pathway to higher-margin, risk-based revenue, though they remain a smaller share of the business. International markets provide diversification and margin-improvement opportunities as fixed overhead is leveraged. Home-based dialysis and the Elara Caring partnership could reposition DaVita across the care continuum beyond the clinic.
Competitive and regulatory risks persist. Fresenius remains a formidable competitor, and reimbursement policy is a recurring source of uncertainty. The pace at which clinical initiatives — vaccination programs, GLP-1 adoption, and advanced dialysis technologies — translate into lower mortality and higher treatment volumes will be a defining variable, with management suggesting full benefits may not materialize until around 2029. Consensus expectations currently reflect a moderately optimistic stance, but the wide range of analyst price targets underscores genuine uncertainty about how quickly these structural shifts convert into sustained growth.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BND | 71.33 | 0.42 | +0.59% |
| Vanguard Total Bond Market ETF (BND) | |||
| UUPP | 25.16 | -0.01 | -0.04% |
| Principal CLO ETF (UUPP) | |||
| TFLR | 50.24 | -0.09 | -0.18% |
| T. Rowe Price Floating Rate ETF (TFLR) | |||
| FNK | 61.01 | -0.86 | -1.39% |
| First Trust Mid Cap Value AlphaDEX Fund (FNK) | |||
| DVYA | 46.89 | -0.80 | -1.68% |
| iShares Asia/Pacific Dividend ETF (DVYA) | |||
A.I.dvisor indicates that over the last year, DVA has been loosely correlated with FMS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVA jumps, then FMS could also see price increases.
| Ticker / NAME | Correlation To DVA | 1D Price Change % | ||
|---|---|---|---|---|
| DVA | 100% | +3.00% | ||
| FMS - DVA | 39% Loosely correlated | +1.54% | ||
| CON - DVA | 33% Loosely correlated | +0.94% | ||
| UHS - DVA | 26% Poorly correlated | +2.54% | ||
| PNTG - DVA | 25% Poorly correlated | +1.61% | ||
| ASTH - DVA | 25% Poorly correlated | +0.77% | ||
More | ||||
| Ticker / NAME | Correlation To DVA | 1D Price Change % |
|---|---|---|
| DVA | 100% | +3.00% |
| Hospital/Nursing Management industry (48 stocks) | 1% Poorly correlated | -0.69% |
a provider of integrated dialysis services for patients suffering from chronic kidney failure
Industry HospitalNursingManagement
DVA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 26 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 65%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DVA as a result. In 51 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
DVA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DVA crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
The 50-day moving average for DVA moved below the 200-day moving average on November 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
The Aroon Indicator for DVA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DVA's RSI Indicator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where DVA advanced for three days, in 245 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
DVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 7 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. DVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-15.956) is normal, around the industry mean (204.532). P/E Ratio (15.431) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.436) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.968) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.